SCHEMBL1384331

SCHEMBL1384331

Cc1cc(Nc2ncc(CCc3ccnc(O)c3)c3ccccc23)ccc1C(C)C

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 1/20 0.36
▸ NR3C2 P08235 4/20 0.36
▸ KDR P35968 5/20 0.33
▸ FLT1 P17948 4/20 0.33
▸ MAPT P10636 5/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ GAA P10253 2/20 0.31
▸ SMN1; SMN2 Q16637 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ PDGFRB P09619 3/20 0.31
▸ KIT P10721 3/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ TP53 P04637 1/20 0.30
▸ POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1383073 0.87 CCNK (0.35) NAMPTNR3C2KDRFLT1MAPT
SCHEMBL1383433 0.84 NAMPT (0.47) NAMPTKDRFLT1MAPTMEN1
SCHEMBL1383890 0.83 GAA (0.37) NAMPTKDRMAPTMEN1NPC1
SCHEMBL7205123 0.81 FLT1 (0.44) NAMPTKDRFLT1LMNASMN1; SMN2
SCHEMBL1386144 0.80 NR3C2 (0.34) NR3C2KDRFLT1MAPTMEN1
SCHEMBL1382827 0.77 EGFR (0.48) NR3C2KDRFLT1MEN1LMNA
SCHEMBL13955413 0.73 KDR (0.37) KDRFLT1MAPTGAASMN1; SMN2
SCHEMBL1385761 0.72 KDR (0.39) NAMPTNR3C2KDRFLT1PDGFRB
SCHEMBL4825401 0.72 GRM4 (0.39) NR3C2KDM4ECYP1A2
SCHEMBL1383698 0.72 GRM4 (0.39) NR3C2KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4837864-B2 — — 2011-12-14 — — JP claimed
US-7323474-B2 Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase NOVARTIS AG (CH) 2008-01-29 — — US claimed
EP-1254138-B1 PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE NOVARTIS AG (CH) 2005-05-11 — — EP claimed
US-20040209894-A1 Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase BOLD GUIDO 2004-10-21 — — US claimed
US-6706731-B2 WITH ISOQUINOLINE DERIVATIVES AS ANTITUMOR AGENTS NOVARTIS AG (CH) 2004-03-16 — — US claimed
US-20030158409-A1 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase NOVARTIS AG (CH) 2003-08-21 — — US claimed
EP-1254138-A1 PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE Novartis AG (CH) 2002-11-06 — — EP claimed
WO-2001058899-A1 PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE NOVARTIS AG (CH) 2001-08-16 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209894-A1 Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase FLT1, FLT4, KDR NAMPT 599/4885NR3C2 1371/4885KDR 3/4885
US-20030158409-A1 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase FLT1, FLT4, KDR NAMPT 442/4885NR3C2 1391/4885KDR 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback